HRP20171515T1 - Spojevi fenoksietilpiperidina - Google Patents

Spojevi fenoksietilpiperidina Download PDF

Info

Publication number
HRP20171515T1
HRP20171515T1 HRP20171515TT HRP20171515T HRP20171515T1 HR P20171515 T1 HRP20171515 T1 HR P20171515T1 HR P20171515T T HRP20171515T T HR P20171515TT HR P20171515 T HRP20171515 T HR P20171515T HR P20171515 T1 HRP20171515 T1 HR P20171515T1
Authority
HR
Croatia
Prior art keywords
pharmaceutically acceptable
compound
acceptable salt
image
intended
Prior art date
Application number
HRP20171515TT
Other languages
English (en)
Croatian (hr)
Inventor
Matthew Allen Schiffler
Jeremy Schulenburg York
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of HRP20171515T1 publication Critical patent/HRP20171515T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HRP20171515TT 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina HRP20171515T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261665951P 2012-06-29 2012-06-29
US201361779099P 2013-03-13 2013-03-13
PCT/US2013/046684 WO2014004229A1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds
EP13734248.1A EP2867207B1 (en) 2012-06-29 2013-06-20 Phenoxyethyl piperidine compounds

Publications (1)

Publication Number Publication Date
HRP20171515T1 true HRP20171515T1 (hr) 2017-11-17

Family

ID=48746666

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20171515TT HRP20171515T1 (hr) 2012-06-29 2013-06-20 Spojevi fenoksietilpiperidina

Country Status (42)

Country Link
US (2) US8962659B2 (cg-RX-API-DMAC7.html)
EP (1) EP2867207B1 (cg-RX-API-DMAC7.html)
JP (1) JP6127136B2 (cg-RX-API-DMAC7.html)
KR (1) KR101653476B1 (cg-RX-API-DMAC7.html)
CN (1) CN104411684B (cg-RX-API-DMAC7.html)
AP (1) AP2014008164A0 (cg-RX-API-DMAC7.html)
AR (1) AR091429A1 (cg-RX-API-DMAC7.html)
AU (1) AU2013280875B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031616B1 (cg-RX-API-DMAC7.html)
CA (1) CA2875569C (cg-RX-API-DMAC7.html)
CL (1) CL2014003535A1 (cg-RX-API-DMAC7.html)
CO (1) CO7151507A2 (cg-RX-API-DMAC7.html)
CR (1) CR20140553A (cg-RX-API-DMAC7.html)
CY (1) CY1119425T1 (cg-RX-API-DMAC7.html)
DK (1) DK2867207T3 (cg-RX-API-DMAC7.html)
DO (1) DOP2014000287A (cg-RX-API-DMAC7.html)
EA (1) EA024392B1 (cg-RX-API-DMAC7.html)
EC (1) ECSP14033267A (cg-RX-API-DMAC7.html)
ES (1) ES2644812T3 (cg-RX-API-DMAC7.html)
GT (1) GT201400288A (cg-RX-API-DMAC7.html)
HR (1) HRP20171515T1 (cg-RX-API-DMAC7.html)
HU (1) HUE034425T2 (cg-RX-API-DMAC7.html)
IL (1) IL236219A (cg-RX-API-DMAC7.html)
JO (1) JO3296B1 (cg-RX-API-DMAC7.html)
LT (1) LT2867207T (cg-RX-API-DMAC7.html)
MA (1) MA37686B1 (cg-RX-API-DMAC7.html)
ME (1) ME02840B (cg-RX-API-DMAC7.html)
MX (1) MX345324B (cg-RX-API-DMAC7.html)
MY (1) MY173878A (cg-RX-API-DMAC7.html)
NZ (1) NZ701933A (cg-RX-API-DMAC7.html)
PE (1) PE20150182A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015500009B1 (cg-RX-API-DMAC7.html)
PL (1) PL2867207T3 (cg-RX-API-DMAC7.html)
PT (1) PT2867207T (cg-RX-API-DMAC7.html)
RS (1) RS56452B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201408641UA (cg-RX-API-DMAC7.html)
SI (1) SI2867207T1 (cg-RX-API-DMAC7.html)
TN (1) TN2014000501A1 (cg-RX-API-DMAC7.html)
TW (1) TWI599561B (cg-RX-API-DMAC7.html)
UA (1) UA114325C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014004229A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201408632B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين
TWI636046B (zh) 2013-05-17 2018-09-21 美國禮來大藥廠 苯氧基乙基二氫-1h-異喹啉化合物
SI3083562T1 (sl) * 2013-12-17 2017-11-30 Eli Lilly And Company Derivati fenoksietil cikličnih aminov in njihova aktivnost kot modulatorji EP4 receptorja
CR20180323A (es) 2015-11-20 2018-08-06 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituídos como moduladores de los receptores de pge2
WO2018210994A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Phenyl derivatives as pge2 receptor modulators
CA3063632A1 (en) 2017-05-18 2018-11-22 Idorsia Pharmaceuticals Ltd Benzofurane and benzothiophene derivatives as pge2 receptor modulators
KR102626982B1 (ko) 2017-05-18 2024-01-18 이도르시아 파마슈티컬스 리미티드 Pge2 수용체 조절제로서의 피리미딘 유도체
ES2896476T3 (es) 2017-05-18 2022-02-24 Idorsia Pharmaceuticals Ltd Derivados de pirimidina
PE20191787A1 (es) 2017-05-18 2019-12-24 Idorsia Pharmaceuticals Ltd Derivados de indol n-sustituidos
EP3889134B1 (en) 2019-01-22 2024-09-25 Keythera (Suzhou) Pharmaceuticals Co. Ltd. Compound for inhibiting pge2/ep4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof
EP4245301A4 (en) 2020-11-13 2024-08-21 ONO Pharmaceutical Co., Ltd. TREATMENT OF CANCER BY COMBINED USE OF AN EP4 ANTAGONIST AND AN IMMUNE CHECKPOINT INHIBITOR
GB202211232D0 (en) 2022-08-02 2022-09-14 Heptares Therapeutics Ltd Prostaglandin EP4 receptor agonist compounds

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2500157C2 (de) 1975-01-03 1983-09-15 Hoechst Ag, 6230 Frankfurt N-Acyl-4-(2-aminoäthyl)-benzoesäuren, deren Salze und Ester, Verfahren zu deren Herstellung und deren Verwendung
BR0308738A (cg-RX-API-DMAC7.html) * 2002-03-18 2005-01-11
CN1735597A (zh) * 2003-01-10 2006-02-15 霍夫曼-拉罗奇有限公司 作为前列腺素激动剂的2-哌啶酮衍生物
AU2004268839A1 (en) 2003-09-03 2005-03-10 Pfizer Inc. Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists
US20050105732A1 (en) 2003-11-17 2005-05-19 Hutchings George T. Systems and methods for delivering pre-encrypted content to a subscriber terminal
ES2327760T3 (es) * 2004-05-04 2009-11-03 Raqualia Pharma Inc Compuestos de aril-heteroaril-amida ortosustituidos.
KR20070006891A (ko) * 2004-05-04 2007-01-11 화이자 인코포레이티드 치환된 메틸 아릴 또는 헤테로아릴 아미드 화합물
US7592364B2 (en) * 2006-02-28 2009-09-22 Allergan, Inc. Substituted gamma lactams as therapeutic agents
CA2648729A1 (en) 2006-04-24 2007-11-01 Merck Frosst Canada Ltd. Indole amide derivatives as ep4 receptor antagonists
EP2035376B1 (en) 2006-06-12 2014-08-27 Merck Canada Inc. Indoline amide derivatives as ep4 receptor ligands
WO2008092860A1 (en) * 2007-01-30 2008-08-07 Janssen Pharmaceutica N.V. Bicyclic derivatives as ep4 agonists
DK2565191T3 (da) 2008-05-14 2014-11-10 Astellas Pharma Inc 4-(Indol-7-ylcarbonylaminomethyl)cyclohexancarboxylsyrederivater som EP4-receptorantagonister der er anvendelige til behandlingen af kronisk nyresvigt eller diabetisk nephropati
JP5536773B2 (ja) 2008-08-14 2014-07-02 ベータ・ファーマ・カナダ・インコーポレイテッド Ep4受容体アンタゴニストとしてのヘテロ環式アミド誘導体
CA2789665C (en) 2010-02-22 2020-06-16 Raqualia Pharma Inc. Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases
JP5956448B2 (ja) * 2010-09-21 2016-07-27 エーザイ・アール・アンド・ディー・マネジメント株式会社 医薬組成物
US9120824B2 (en) 2011-07-04 2015-09-01 Rottapharm Biotech S.R.L. Cyclic amine derivatives as EP4 receptor agonists
DK2729445T3 (en) * 2011-07-04 2016-01-18 Rottapharm Biotech Srl CYCLIC AMINE DERIVATIVES AS EP4 RECEPTOR ANTAGONISTS
JO3296B1 (ar) * 2012-06-29 2018-09-16 Lilly Co Eli مركبات فينوكسي إيثيل بيبريدين

Also Published As

Publication number Publication date
CA2875569C (en) 2016-04-19
UA114325C2 (uk) 2017-05-25
MA37686A1 (fr) 2016-09-30
JP2015522018A (ja) 2015-08-03
KR20150013893A (ko) 2015-02-05
PE20150182A1 (es) 2015-02-13
NZ701933A (en) 2017-01-27
TWI599561B (zh) 2017-09-21
AR091429A1 (es) 2015-02-04
US20150126555A1 (en) 2015-05-07
JO3296B1 (ar) 2018-09-16
CL2014003535A1 (es) 2015-05-08
US9402838B2 (en) 2016-08-02
MA37686B1 (fr) 2017-04-28
AP2014008164A0 (en) 2014-12-31
MX2014015953A (es) 2015-07-17
CO7151507A2 (es) 2014-12-29
PT2867207T (pt) 2017-11-01
PH12015500009A1 (en) 2015-03-02
IL236219A (en) 2017-12-31
RS56452B1 (sr) 2018-01-31
ES2644812T3 (es) 2017-11-30
GT201400288A (es) 2015-08-27
MX345324B (es) 2017-01-25
TW201412717A (zh) 2014-04-01
EP2867207A1 (en) 2015-05-06
CY1119425T1 (el) 2018-03-07
CR20140553A (es) 2015-02-04
TN2014000501A1 (en) 2016-03-30
EP2867207B1 (en) 2017-08-09
ME02840B (me) 2018-01-20
BR112014031616A2 (pt) 2017-06-27
AU2013280875A1 (en) 2014-12-04
EA201492255A1 (ru) 2015-03-31
US20140005226A1 (en) 2014-01-02
IL236219A0 (en) 2015-02-01
SG11201408641UA (en) 2015-01-29
EA024392B1 (ru) 2016-09-30
US8962659B2 (en) 2015-02-24
WO2014004229A1 (en) 2014-01-03
ZA201408632B (en) 2017-06-28
PH12015500009B1 (en) 2020-10-09
DK2867207T3 (en) 2017-09-11
MY173878A (en) 2020-02-26
CN104411684B (zh) 2016-08-24
KR101653476B1 (ko) 2016-09-01
AU2013280875B2 (en) 2015-09-24
PL2867207T3 (pl) 2018-01-31
CA2875569A1 (en) 2014-01-03
JP6127136B2 (ja) 2017-05-10
HUE034425T2 (en) 2018-02-28
LT2867207T (lt) 2017-10-10
CN104411684A (zh) 2015-03-11
ECSP14033267A (es) 2015-09-30
BR112014031616B1 (pt) 2022-06-21
HK1203937A1 (en) 2015-11-06
SI2867207T1 (sl) 2017-10-30
DOP2014000287A (es) 2015-01-31

Similar Documents

Publication Publication Date Title
HRP20171515T1 (hr) Spojevi fenoksietilpiperidina
ME02910B (me) Spojevi tetrahidropirolotiazina
ME02896B (me) Fenoksietilni derivati prstenastog amina i njihova aktivnost kao modulatora receptora ep4
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
HRP20181048T1 (hr) Neuroaktivni 19-alkoksi-17-supstituirani steroidi, korisni u postupcima liječenja
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
HRP20201949T1 (hr) 7-benzil-4-(4-(trifluorometil)benzil)-1,2,6,7,8,9-heksahidroimidazo[1,2-a]pirido[3,4-e]pirimidin-5(4h)-on i njegove soli i njihova primjena u terapiji
NZ612000A (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
HRP20171512T1 (hr) Derivati betulina
HRP20161103T1 (hr) Kemijski spojevi
HRP20161379T1 (hr) Inhibitori hepatitis c virusa
EA201401150A1 (ru) Аминоиндолилзамещенные имидазолпиримидины и их применение в качестве лекарственных средств
MY174188A (en) Heterocyclyl compounds
HRP20120830T1 (hr) Imidazolkarboksamidi
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
EA201391029A1 (ru) Производные оксазина и их применение при лечении неврологических нарушений
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
ME02576B (me) Derivati tetrahidropirolotiazina kao inhibitori bace
HRP20180237T4 (hr) Metode za liječenje hcv-a
MX375925B (es) Compuestos imidazo[1,2-a]pirazin-1-il-benzamida para tratar atrofia muscular espinal.
BR112014005407A2 (pt) composto, composição farmacêutico, uso do composto ou um sal farmaceuticamente aceitável do mesmo, e, método de tratamento de um paciente infectado com hcv
BR112015022077A2 (pt) composto de pirazol-amida e usos medicinais do mesmo
EA201491321A1 (ru) Фторметил-5,6-дигидро-4н-[1,3]оксазины
HRP20171824T1 (hr) (TIENO[2,3-b][1,5]BENZOKSAZEPIN-4-IL)PIPERAZIN-1-ILNI SPOJEVI S DVOJNOM AKTIVNOŠĆU INVERZNIH AGONISTA H1 I ANTAGONISTA 5-HT2A